France
Valneva, founded in 2013, is a France-based specialty vaccine company renowned for addressing infectious diseases with significant unmet needs. With a forward-thinking approach, the company prides itself on offering first-, best-, or only-in-class vaccine solutions. Their portfolio includes the world’s first and only chikungunya vaccine and a promising Lyme disease vaccine candidate in advanced clinical development, in partnership with Pfizer.
The company demonstrates a robust commercialization strategy, leveraging revenues from travel vaccines to advance its pipeline, including vaccine candidates for diseases like the Zika virus. Valneva's expertise spans across multiple countries, including Austria, Sweden, the United Kingdom, France, Canada, and the U.S., with about 700 employees.
Their latest funding, a $41.30M grant investment on 22 July 2024 from Horizon Europe and the Coalition for Epidemic Preparedness Innovations, reinforces its strategic direction towards innovative health solutions.
